Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil PK with Tipranavir/Ritonavir in Healthy Males
NCT02253862Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tipranavir in human immunodeficiency virus infection (HIV), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Plasma Concentration for Tadalafil up to 72 hours, Plasma Concentration at 12 hours for Tadalafil and 2 more. Started Dec 2005; status: completed.
02
Drugs
tipranavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02253862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253862.